Chlorfenade tablets

Among them, diclofenac sodium is a phenylacetic acid derivative, which has analgesic, anti-inflammatory and antipyretic effects. Its analgesic effect is stronger than aspirin and indomethacin, about 26-50 times that of aspirin, and is a peripheral analgesic. It is characterized by strong efficacy, mild adverse reactions, small dosage, and small individual differences. Codeine phosphate is a methyl derivative of morphine, which has a direct inhibitory effect on the cough center of the medulla oblongata, and has a strong and rapid antitussive effect, with an intensity of about 1/4 of morphine. In addition, it also has analgesic and sedative effects, and the intensity of analgesic effect is about 1/10 of morphine, but it is still stronger than general antipyretic analgesics, and is a central weak opioid analgesic. Taking this product may cause gastrointestinal reactions, respiratory depression is very weak, and addiction is low.

This product is a compound preparation, and its components are: each tablet contains 25 mg of diclofenac sodium and 15 mg of codeine phosphate.

This product is white or off-white tablets

Oral administration: Adults: 1-2 tablets at a time, 3 times a day.

Mainly gastrointestinal symptoms, such as stomach discomfort, nausea, vomiting, etc., with an incidence of about 10%. Literature reports also show dizziness, drowsiness, rash, itching, edema, jaundice, respiratory depression, constipation or bleeding tendency. Diclofenac sodium alone can cause the following adverse reactions: 1. It can cause gastrointestinal reactions such as headache and abdominal pain, constipation, diarrhea, stomach burning, nausea, indigestion, etc.; 2. Occasionally headache, dizziness, and vertigo. Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) increase; 3. Rarely, renal function declines, which can lead to water and sodium retention, manifested by low urine volume, facial edema, and sudden weight gain. Very few can cause arrhythmia, tinnitus, etc.; 4. Rare: rash, gastrointestinal bleeding, peptic ulcer, hematemesis, black stool, gastrointestinal ulcer, perforation, hemorrhagic diarrhea, drowsiness, allergic reactions such as asthma, hepatitis, edema; 5. There is a possibility of causing bone marrow suppression or aggravating it. Codeine phosphate alone may cause the following adverse reactions: 1. Common adverse reactions include: 1-1, psychological abnormality or hallucination; 1-2, weak, slow or irregular breathing; 1-3, fast or slow heart rate, abnormal. 2. Rare adverse reactions: 2-1, convulsions, tinnitus, tremors or uncontrollable muscle movements, etc.; 2-2, allergic reactions such as urticaria, itching, rash or facial edema; 2-3, depression and muscle rigidity, etc. 3. Long-term use may cause dependence. The tendency of common doses to cause dependence is weaker than that of other morphine drugs. Typical symptoms are: loss of appetite, diarrhea, toothache, nausea and vomiting, runny nose, chills, sneezing, yawning, sleep disorders, stomach cramps, sweating, weakness, increased heart rate, emotional agitation or unexplained fever.

1. Contraindicated for cardiac, functional and undiagnosed pain. 2. Contraindicated for patients allergic to aspirin or morphine. 3. Patients known to be allergic to diclofenac sodium. 4. Patients who have asthma, urticaria or allergic reactions after taking aspirin or other non-steroidal anti-inflammatory drugs. 5. Contraindicated for the treatment of perioperative pain during coronary artery bypass grafting (CABG). 6. Patients with a history of gastrointestinal bleeding or perforation after the use of non-steroidal anti-inflammatory drugs. 7. Patients with active gastrointestinal ulcers/bleeding, or patients with recurrent ulcers/bleeding in the past. 8. Patients with severe heart failure. 9. Contraindicated for children under 12 years old. 10. Contraindicated for breastfeeding women. 11. Contraindicated for patients known to be ultra-rapid metabolizers of CYP2D6.

Precautions for children: This product is contraindicated for children under 12 years old. This product should not be used for children and adolescents aged 12-18 years with chronic respiratory diseases. This product is only used for the treatment of acute (short-term) moderate pain, and can only be used when the pain cannot be relieved by other non-steroidal anti-inflammatory drugs (such as acetaminophen or ibuprofen). Precautions for pregnancy and lactation: 1. This product contains two main drugs that can pass through the placenta and affect the fetus, so it is contraindicated for pregnant women. 2. It is contraindicated for lactating women. Both main drugs contained in this product can be excreted from breast milk. Codeine can be secreted into breast milk when used by lactating mothers. In mothers with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into breast milk is very small and dose-dependent. However, if the mother is an ultra-fast metabolizer of codeine, symptoms of drug overdose may occur, such as extreme drowsiness, confusion or shallow breathing. The concentration of morphine in the mother's breast milk will also increase, and it can cause life-threatening or fatal adverse reactions in infants. Precautions for the elderly: Use with caution.

When the codeine phosphate in this product is used together with central nervous system depressants, an additive effect may occur. Diclofenac sodium can increase the blood concentration of steroidal anti-inflammatory drugs; acetylsalicylic acid can reduce the blood concentration of diclofenac sodium. Diclofenac sodium: 1. When used with alcohol or other non-steroidal anti-inflammatory drugs, it increases gastrointestinal adverse reactions and the risk of ulcers. Long-term use with acetaminophen may increase the toxic side effects on the kidneys; 2. When used with aspirin or other salicylic acid drugs, the efficacy is not enhanced, but the incidence of gastrointestinal adverse reactions and bleeding tendency increases; 3. When used with anticoagulants such as heparin and dicoumarol and platelet aggregation inhibitors, there is an increased risk of bleeding; 4. When used with furosemide, the latter's sodium excretion and antihypertensive effects are weakened; 5. When used with verapamil and nifedipine, the blood concentration of this product increases; 6. This product can increase The blood concentration of digoxin, when used together, the dose of digoxin should be adjusted; 7. When this product is used together with antihypertensive drugs, it can affect the latter's antihypertensive effect; 8. Probenecid can reduce the excretion of this product, increase the blood concentration, and thus increase toxicity, so it is advisable to reduce the dose of this product when used together; 9. This product can reduce the excretion of methotrexate and increase its blood concentration; it can even reach the toxic level, so this product should not be used with medium or large doses of methotrexate; 10. This product can reduce the effect of insulin and other hypoglycemic drugs and increase blood sugar; 11. When used together with potassium-sparing diuretics, it can cause hyperkalemia; 12. Aspirin can reduce the bioavailability of this product. Codeine phosphate: 1. When this product is used in combination with anticholinergic drugs, it can aggravate the adverse reactions of constipation or urinary retention; 2. When used in combination with methadone or other morphine drugs, it can aggravate the central respiratory depression; 3. When used in combination with muscle relaxants, respiratory depression is more significant.

Keep away from light and store in sealed container.

40 mg (each tablet contains 25 mg of diclofenac sodium and 15 mg of codeine phosphate

36 months

Shanxi Taiyuan Jinyang Pharmaceutical Factory

• Founded in:

  1989-08-29

• Address:

  No. 22, Minhang South Road, Xiaodian District, Taiyuan City

• Tax NO.:

  911401051100866506

• Registered Funds:

  11.56938626 million yuan

• Email:

  Log in to view